


What is the UroLift® System?

The UroLift® System is a minimally invasive procedure to treat an enlarged prostate. It is a proven option for patients looking for an alternative to medications or major surgery. The enlarged prostate procedure that does not require heating, cutting, or destruction of prostate tissue.¹⁻⁷



**Results may vary*

UroLift System Benefits


Patients have been shown to have a better recovery experience than TURP, with durable results and no new and lasting sexual dysfunction^{*8-14}

- **Rapid** relief and recovery in days, not months^{8,15}
- **Low** catheter rate¹⁵
- The BPH procedure that does not destroy tissue¹⁻⁷
- Proven **durability** through five years¹⁶
- **Real world** outcomes largely consistent with randomized controlled data¹⁷

Warning: This device contains stainless steel and nitinol, an alloy of nickel and titanium. Persons with allergic reactions to these metals may suffer an allergic reaction to this implant. Prior to implantation, patients should be counseled on the materials contained in the device, as well as potential for allergy/hypersensitivity to these materials.

*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T.¹⁶ pivotal study

UroLift System: UL400-AM



UroLift® Permanent Implant

UroLift® Delivery Device

The UroLift® Delivery Device is inserted transurethally through a rigid sheath under cystoscopic visualization in order to reach the targeted area of obstruction.

The obstructing prostatic lobes are retracted by small permanent UroLift Implants which are deployed via a needle that comes out of the delivery device.

Each UroLift Delivery Device contains one UroLift Implant.⁹



ANCILLARY PROCEDURE KIT

2.9 mm, 0°, 36 cm Telescope
(UL-SCOPE)




20F Sheath
(UL-SHEATH)



Visual Obturator
(UL-VO)



OTHER



Cleaning and Storage Basket
(UL-TRAY)

1. Lokeshwar, Transl Androl Urol 2019; 2. Miano, Med Sci Monit 2008; 3. Mirakhur, Can Assoc Rad J 2017; 4. Woo, BJUI 2011; 5. McVary, J Urol 2016; 6. Gilling, Can J Urol 2020; 7. Kadner, World J Urol 2016; 8. Roehrborn, Can J Urol 2015; 9. Roehrborn, J Urology 2013; 10. AUA BPH Guidelines 2003, 2010, 2018 amended 2019; 11. Naspro, Eur Urol 2009; 12. Montorsi, J Urol 2008; 13. McVary, J Sex Med 2016; 14. Sonksen Eur Urol 2015; 15. Shore Can J Urol 2014; 16. Roehrborn et al. Can J Urol 2017; 17. Eure et al J Endourol 2019

Indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 50 years or older. As with any medical procedure, individual results may vary. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.9 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult the Instructions for Use (IFU) for more information.

The products in this document may not be available in all countries. Please contact your local representative. Please check your local regulatory approval status. Refer to the applicable Instructions for Use for the indications approved in your geography.

BPH Relief. In Sight. UroLift, the UroLift logo, NeoTract, the NeoTract logo, Teleflex and the Teleflex logo are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. Registro ANVISA: 80117580890 and 80117589018.

© 2021 Teleflex Incorporated. All rights reserved. MC-007134 LA EN
For more product information contact la.cs@teleflex.com